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NK cells have direct activity against fungal pathogens. Using an unbiased systematic approach, Li et al.
(2013) find that NKp30 is a major NK cell receptor responsible for fungal recognition. Moreover, diminished
NKp30 expression is associated with reduced antifungal activity in NK cells isolated from HIV-infected
persons.Natural killer (NK) cells are cytotoxic lym-
phocytes, which are important effector
cells in viral infections and anti-tumor
immunity. Unlike cells of the adaptive
immune system (T and B lymphocytes),
there is no somatic receptor gene rear-
rangement in NK cells. NK cell receptors
are germ-line encoded proteins and com-
prise several transmembrane inhibitory
and activating molecules that regulate
NK cell function and homeostasis. Within
this group are killer-cell-Ig-like-receptors
(KIRs), lectin type receptors, and natural
cytotoxicity receptors (NCRs). The effec-
tor functions of NK cells are determined
by a fine balance of signals received
from these and other receptors, including
the innate immune Toll-like receptors.
The identification and cloning of three
NCRs, NKp46, NKp30, and NKp44, were
achieved in the late 1990s and revealed
that NKp46 and NKp30 are expressed
by NK cells freshly purified from periph-
eral blood, whereas NKp44 is induced
upon NK cell activation (Hudspeth et al.,
2013).
In addition to their central role in de-
fending against tumors and infectious
agents, NK cells have direct activity
against human bacterial, parasitic, and
fungal pathogens. Regarding the latter,
activity has best been studied with
Cryptococcus neoformans, an opportu-
nistic fungus that causes an estimated
million cases of meningitis in AIDS
patients annually (Park et al., 2009). NK
activity requires signaling via the PI3K-
ERK1/2 signaling pathway and is mainly
mediated by the lytic protein perforin
(Wiseman et al., 2007). Similar direct
interactions of NK cells against numerous
other human fungal pathogens have beendescribed, including Candida albicans.
Moreover, whereas several studies have
suggested NK cell recognition of fungi
is a receptor-mediated process, specific
receptors heretofore have not been iden-
tified (Jones et al., 2009; Levitz et al.,
1995).
In the study reported in this issue, Li
and colleagues used an unbiased sys-
tematic approach to identify receptors
used by NK cells for fungal recognition
and microbicidal activity (Li et al., 2013).
The authors generated a panel of mouse
monoclonal antibodies to human NK cells
and found that one of the antibodies
blocked NK cell binding to Cryptococcus.
Further studies established that the
antibody recognized the NK-activating
receptor NKp30 and that NKp30 is neces-
sary for optimal NK cell recognition,
microbial synapse formation, and anti-
microbial activity against C. neoformans
and C. albicans (Figure 1). Additionally,
NKp30 was shown to be required for
perforin degranulation and signaling via
PI3K/Akt and ERK phosphorylation in
response to fungal stimulation. Impor-
tantly, given the strong association
of cryptococcosis with AIDS, Li et al.
(2013) demonstrate that NK cells from
HIV-infected persons have impaired
NKp30 expression, defective fungus-
induced perforin release, and impaired
killing of C. neoformans. Finally, they
establish the proof-of-concept that
these defects can be reversed: in vitro
treatment of NK cells from HIV-infected
persons with the proinflammatory cyto-
kine IL-12, which has been shown to
enhance the antifungal activity of these
cells, restores their NKp30 expression
and fungicidal capacity.Cell Host & Microbe 14These findings have important concep-
tual and practical implications that extend
beyond the identification of the first
NK cell receptor that mediates direct
recognition of fungi. The innate immune
system recognizes fungi via a diverse
array of receptors, including C-type lectin
receptors, Toll-like receptors, scavenger
receptors, and Fc/complement recep-
tors. The findings by Li et al. (2013) sug-
gest that the natural cytotoxicity receptor
NKp30 should be added to the list of
pattern recognition receptors for fungi.
Translationally, the observation that
the defective in vitro antifungal activity
of NK cells from persons with HIV can
be reversed with IL-12 suggests avenues
for treatment of cryptococcosis in HIV-
infected patients. Unfortunately, the
adverse effects of IL-12 administration
probably preclude its use in patients.
More promising perhaps is IFNg, which
has been effectively used as an adjunc-
tive immunotherapy for patients with
cryptococcosis and has been shown to
restore deficient fungus-stimulated IL-12
responses from HIV-positive mononu-
clear cells.
This study represents an important
step toward understanding the mecha-
nisms by which NK cells contribute
to antifungal immunity, yet important
questions remain. Upon IL-12 treatment,
NKp30 expression is upregulated but
the pathway leading to NKp30 induction
downstream of IL-12 exposure and the
mechanism mediating the recovery of
the associated fungal cytotoxicity remain
to be characterized, including whether
the IL-12-augmented response is perforin
dependent. NKp30 expression has also
been shown to increase in HCV-exposed, October 16, 2013 ª2013 Elsevier Inc. 369
Figure 1. Overview of the Mechanism by which NK Cells Recognize
Fungi and Mediate Antimicrobial Activity
Upon an encounter with a fungal human pathogen, NKp30 and possibly other
receptor(s) (Receptor X) on NK cells recognize unknown fungal cell wall li-
gand(s). Recognition triggers signaling via the PI3K/AKT and ERK pathways,
which leads to the formation of a microbial synapse between the NK cell
and the pathogen. NKp30 and other receptor(s) polarize to the microbial syn-
apse together with perforin and F-actin. Lytic degranulation then delivers
effector molecules, such as perforin, to the fungal cell.
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drug users (Golden-Mason
et al., 2010) and in response
to the cytokine IL-2 (Castri-
coni et al., 2003), suggesting
that expression of the recep-
tor can be regulated. Howev-
er, it is unknown whether this
regulation is directly medi-
ated by IL-12 or through an
intermediary such as IFNg.
The study by Li et al. (2013)
wasperformed in vitro using a
humanNKcell lineandexvivo
using NK cells obtained from
human blood. It remains an
open question how important
NK cells are for defenses
against fungal infections
in vivo. In murine models,
while NK cell depletion or
dysfunction has generally re-
sulted in increased suscepti-
bility to experimental fungal
infections, in some studies
deleterious effects have not
been seen. Second, a rela-
tively high effector-to-target
ratio is generally required for
in vitro antifungal activity yet
only about 15% of circulating
human lymphocytes are NK
cells. Finally, while NK cells
are dysfunctional in HIV-in-
fected individuals, it may be
a leap of faith to link NK celldysfunction to susceptibility to Crypto-
coccus and Candida given the pre-
dominant role of CD4+ T cells. Similarly,
primary hemophagocytic lymphohistio-
cytosis, a rare hematologic disorder of
infancywithmanygenetic causes, is asso-
ciatedwith both defectiveNK cell cytotox-
icity and increased susceptibility tomyco-
ses, but it is not clear if the association is
causal given the multiple other immu-
nocompromises that patients with this
disease have.
Remarkably, Li et al. (2013) found
that NKp30 is a receptor for two diverse
fungal species; C. neoformans, a basid-
iomycete, and C. albicans, an asco-
mycete. While the fungal ligand recog-
nized by NKp30 is unknown, it is likely
to be a very well-conserved fungal
‘‘pathogen-associated molecular pat-
tern’’ (PAMP) when one considers that
Cryptococcus and Candida are members
of phyla thought to have diverged at least370 Cell Host & Microbe 14, October 16, 201400 million years ago. Moreover, NKp30
is ‘‘promiscuous’’ in the sense that it rec-
ognizes viruses and parasites in addition
to fungi, suggesting that the PAMP is
more broadly shared among microorgan-
isms. NKp30 is required for NK-mediated
activity against both encapsulated and
acapsular strains of C. neoformans.
Li et al. (2013) speculate that the ligand
recognized by NKp30 lies in the cell wall
rather than being a capsular antigen. If
this is the case, it remains to be explained
how NKp30 would reach this ligand in
encapsulated C. neoformans. Interest-
ingly, Joyce et al. (2011) recently
described that NKp30 displays an I-type
Ig-like topology consisting of eight b
strands forming two antiparallel b sheets.
In Drosophila, the structure of GNBP3, a
pattern recognition receptor capable of
binding the fungal cell wall, consists of
two antiparallel b sheets and belongs to
the immunoglobulin fold family. This re-3 ª2013 Elsevier Inc.ceptor has been described
to specifically recognize long
b-1,3-glucan chains, an
important component of the
fungal cell wall and a very
well conserved PAMP among
fungal species (Mishima
et al., 2009). Finally, it should
be noted that NKp30 is un-
likely to be the sole NK recep-
tor involved in fungal recogni-
tion as inhibition of NKp30
with monoclonal antibodies
or knockdown with siRNA
only partially inhibited conju-
gate formation and perforin
release. In fact, Li et al.
(2013) raise the possibility
that a multistep process is
involved in binding and anti-
fungal effector activity of NK
cells and that additional NK
receptors are involved.
Despite these unanswered
questions, the study reported
by Li and colleagues is a
major step in understanding
the direct role of NK cells
in antifungal immunity and
describes a receptor on
NK cells mediating recog-
nition and antimicrobial acti-
vity of C. neoformans and
C. albicans. Hopefully, these
data will prompt research
aimed at further decipher-ing these questions and designing novel
approaches for the therapy of HIV-asso-
ciated fungal infection.ACKNOWLEDGMENTS
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Human MxA (MX1) protein is an interferon-induced restriction factor for a diverse range of viruses, whereas
the related MxB (MX2) protein was thought to lack such activity. Three recent papers, including one in this
issue of Cell Host & Microbe, show that MxB inhibits human immunodeficiency virus type 1 (HIV-1) infection.Myxovirus resistance (Mx) proteins are
IFN-induced dynamin-like large GTPases
of vertebrates (Haller and Kochs (2011).
Most mammals have two Mx genes
(myxovirus resistance genes 1 and 2)
that arose by gene duplication. The hu-
man MxA protein (encoded by the MX1
gene) has long been recognized as a
potent cell-autonomous restriction factor
with antiviral activity against a range
of pathogenic DNA and RNA viruses,
notably influenza A viruses (Ma¨nz et al.,
2013). In contrast, MxB (encoded by the
MX2 gene and closely linked to MX1 on
chromosome 21) was found to be devoid
of antiviral activity and was considered
to serve cellular functions, such as regu-
lating nucleo-cytoplasmic transport and
cell-cycle progression (King et al., 2004;
Mele´n et al., 1996). Liu et al. (2013) now
report in this issue of Cell Host & Microbe
that MxB (MX2) is an innate immunity
factor that blocks HIV-1 infection. Two
other recent reports published in Nature
(Goujon et al., 2013; Kane et al., 2013)
come to the same conclusion. These
unexpected findings represent a major
advance in our understanding of anti-
retroviral host defense and may provide
clues for designing new strategies to
combat HIV-1 and AIDS.
The human MX genes were cloned at
the University of Zu¨rich, Switzerland,almost 25 years ago (Aebi et al., 1989),
at a time when the AIDS epidemic was
gaining momentum worldwide. How is it
possible that the anti-HIV-1 activity of
MxB remained undetected for such a
long time? MxB was perhaps neglected
owing to the preconceived notion that it
was not antiviral or it was outright missed
because it displays its antiviral function
preferentially in some cell types but not
others. In retrospect, it makes sense that
MxB is part of the IFN-induced antiviral
state, as it was sporadically identified in
large scale screens for IFN-induced anti-
viral factors.
MxA and MxB are closely related (63%
amino acid sequence identity) and share
a similar domain structure and archi-
tecture (Figures 1A and 1B). The crystal
structure of MxA revealed three functional
domains, namely the amino-terminal
globular ‘‘G domain’’ that binds and
hydrolyses GTP, a hinge-like ‘‘bundle
signaling element’’ (BSE) that connects
the ‘‘G domain’’ to the elongated ‘‘stalk’’
domain, and the helical ‘‘stalk,’’ which
mediates self-assembly into oligomers
and serves antiviral effector functions
(Gao et al., 2011). The predicted structure
of MxB is almost superimposable with
that of MxA (Figure 1B). A unique feature
of MxB is that it exists in two isoforms
that are translated as 78 or 76 kDa pro-teins from alternate AUG start codons of
the same mRNA (Mele´n et al., 1996). The
longer isoform contains a nuclear locali-
zation signal (NLS)-like sequence in its
first 25 amino acids and appears to
localize preferentially to nuclear pores,
whereas the 76 kDa form is cytoplasmic.
Recent structural and evolutionary
studies identified critical antiviral speci-
ficity determinants in MxA. A disordered
loop, called L4 that is also present in
MxB protrudes from the stalk (Figure 1B).
An analysis of MxA orthologs from simian
primates identified L4 as a target interface
under positive selection and revealed that
variations in L4 dictate antiviral specificity
toward orthomyxoviruses (Mitchell et al.,
2012). Additional ‘‘hot spots’’ of positive
selection may represent alternative target
specificity determinants.
Now, Liu et al. (2013) demonstrate that
MxB, but not MxA, inhibits the replication
of a well-known HIV-1 strain (NL4-3) in
cell culture. Expression of MxB inhibited
HIV-1 growth in a permissive CD4+ T cell
line while depletion of endogenous MxB
reduced the anti-HIV-1 effect of IFN-a in
a human astroglioma cell line known to
respond well to IFN treatment. These and
additional experiments clearly demon-
strate that MxB is responsible for a large
part of the antiretroviral effect induced by
type I IFNs. It was conceivable that MxB, October 16, 2013 ª2013 Elsevier Inc. 371
